{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:52:39Z","timestamp":1791265959607,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"DOI":"10.1038\/s41581-026-01140-7","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:32:22Z","timestamp":1791214342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preventative nephrology in the cardiovascular\u2013kidney\u2013metabolic era"],"prefix":"10.1038","author":[{"given":"Hellena Hailu","family":"Habte-Asres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"1140_CR1","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele, C. E. et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 148, 1606\u20131635 (2023).","journal-title":"Circulation"},{"key":"1140_CR2","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1161\/CIR.0000000000001453","volume":"154","author":"CE Ndumele","year":"2026","unstructured":"Ndumele, C. E. et al. 2026 AHA\/ACC\/ADA\/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 154, e50\u2013e158 (2026).","journal-title":"Circulation"},{"key":"1140_CR3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.kint.2026.03.031","volume":"110","author":"A Levin","year":"2026","unstructured":"Levin, A. et al. The kidney in the middle: Kidney Disease: Improving Global Outcomes (KDIGO) guidelines address multiple key components of cardiovascular-kidney-metabolic syndrome. Kidney Int 110, 570\u2013582 (2026).","journal-title":"Kidney Int"},{"key":"1140_CR4","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/j.numecd.2024.09.004","volume":"34","author":"HH Habte-Asres","year":"2024","unstructured":"Habte-Asres, H. H. et al. Organisational initiatives to improve care in the prevention and management of cardiometabolic conditions: a scoping review. Nutr. Metab. Cardiovasc. Dis. 34, 2630\u20132641 (2024).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"1140_CR5","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1016\/S0140-6736(26)00608-2","volume":"407","author":"J Valabhji","year":"2026","unstructured":"Valabhji, J. et al. Interventions for the prevention and management of cardiometabolic multiple long-term conditions. Lancet 407, 2668\u20132684 (2026).","journal-title":"Lancet"},{"key":"1140_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2025.20834","volume":"335","author":"BL Neuen","year":"2026","unstructured":"Neuen, B. L. et al. SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: a meta-analysis. JAMA 335, 233\u2013244 https:\/\/doi.org\/10.1001\/jama.2025.20834 (2026).","journal-title":"JAMA"},{"key":"1140_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 https:\/\/doi.org\/10.1056\/NEJMoa2403347 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1140_CR8","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219\u20132229 https:\/\/doi.org\/10.1056\/NEJMoa2025845 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1140_CR9","doi-asserted-by":"publisher","first-page":"e15381","DOI":"10.1111\/dme.15381","volume":"42","author":"HH Habte-Asres","year":"2025","unstructured":"Habte-Asres, H. H., Rosenthal, M., Nitsch, D. & Wheeler, D. C. Closing the policy gap in diabetes care for individuals with advanced CKD. Diabet. Med. 42, e15381 https:\/\/doi.org\/10.1111\/dme.15381 (2025).","journal-title":"Diabet. Med."},{"key":"1140_CR10","doi-asserted-by":"publisher","first-page":"sfaf049","DOI":"10.1093\/ckj\/sfaf049","volume":"18","author":"RW Major","year":"2025","unstructured":"Major, R. W. et al. Integrated primary and secondary care optimizes the management of people with CKD\u2014the LUCID project. Clin. Kidney J. 18, sfaf049 (2025).","journal-title":"Clin. Kidney J."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01140-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01140-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01140-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:03:44Z","timestamp":1791263024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01140-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":10,"alternative-id":["1140"],"URL":"https:\/\/doi.org\/10.1038\/s41581-026-01140-7","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"5 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.H.H.-A has received speaker honoraria from Novo Nordisk, AstraZeneca, Pfizer and Bayer. D.C.W. has an ongoing consultancy contract with AstraZeneca and has received payments for consultancy and\/or speaking activities from multiple companies, including Amgen, Astellas, Bayer, Boehringer Ingelheim, Eledon, GSK, Galderma, Gilead, Janssen, Mundipharma, Menarini, MSD, Novo Nordisk, Pharmacosmos, Tricida, and Vifor.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}